EFFICACY OF PHARMACOLOGICAL THERAPY IN PATIENTS WITH ATYPICAL CHRONIC HERPES VIRUS INFECTIONS

The efficacy of the integration program for the immune system correction (IPCIS) was evaluated in patients suffering from atypical chronic active herpes virus infections (ACA-HVI). The use of recombinant interferon alfa2b (recIFNa2b) in combination with arginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine (hexa-peptide-GP), inosine pranobex, famciclovir was included in this program. It is shown that the use of recIFNa2b in the form of rectal suppositories at a dose of 3 million IU according to the scheme: 3 million IU per day for 21 days, then 2 million IU per day – 21 days; further 1 million IU for 21 days; then 1 million IU three times a week for two weeks; then 1 million IU twice a week for two weeks; as well as 36,000 IU /1 g topical in the gel form for applications to the nasal mucosa, posterior pharyngeal wall and tonsils with a frequency of up to 3 – 5 times a day; GP in the form of a solution for intramuscular administration 1 mL according to the scheme: 1 mL 1 once a day 10-day courses ´1 once a month for within 3 months; inosine pranobex in per oral administration at the rate of 50 mg/kg/day – 10-day courses ´ 1 once a month, course 3 months; famciclovir according to the scheme: 1500 mg per day for 10 days once a month with a break of 20 days, a course of 3 months of inosine pranobex revealed positive immunological changes. A regression of the incidence of neutrophil granulocyte defects from 86.3% to 34.2%; deficiency of CD3+CD8+ subpopulations from 76.4 to 28.4%; and CD3+CD56+ from 83.2% to 48.2% as well as a decrease in the deficit of natural-killer cells from 36.7% to 23.1% (p £ 0,05) were observed. The clinical efficacy of the therapy revealed through a 2.3-fold decrease in the frequency of HSV1/HSV2 relapses from 10.2 to 4.5 relapses per year (p < 0.05) and 1.8-fold decrease in their duration from 8.1 days to 4.4 days (p < 0.05). The severity of clinical symptoms/criteria signs of myeloecephalitis/chronic fatigue syndrome decreased from 53.5 to 30.5 points (p < 0.05). It is shown that levels of serum IL6, IL1b, and IL1Ra may be used as biomarkers for assessing the level of systemic inflammation and neuroimmunoinflammation, as well as in evaluation the regression of the latter in case of mixed ACA-HVI. Thus, the results obtained showed the high efficiency of the integration program for the correction of the immune system in patients with ACA-HVI. © 2023 Izdatel'stvo Meditsina. All rights reserved.